Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

The use of immune checkpoint inhibitors (ICIs) is rapidly increasing as more combinations and clinical indications are approved in the field of genitourinary malignancies. Most immunotherapeutic agents being approved are for the treatment of renal cell carcinoma and bladder cancer, which mainly invo...

Full description

Bibliographic Details
Main Authors: Haoran Li, Kamal K. Sahu, Benjamin L. Maughan
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
genitourinary cancer
immunotherapy
immunotherapy-related toxicity
immune checkpoint inhibitor
immunosuppression
immunotherapy rechallenge
Online Access:https://www.mdpi.com/2072-6694/14/10/2460

Similar Items

Similar Items